The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2016 | Safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (SCLC)

Name: Safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (SCLC)
Uploaded: 2016-06-03T00:00:00.000Z
Duration: 7 min 14 s
Description: Press brief by Charles Rudin, MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

Charles Rudin • 3 Jun 2016

ASCO 2016

Lung Cancer Rovalpituzumab tesirine

Press brief by Charles Rudin, MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.